“Having the opportunity to really sit down and talk with some of the most creative people in the world, including a Nobel Prize nominee, was something I’ll never forget and something I never thought I’d be able to do at this stage of my career.” – Cijian Feng, MBS ’12

TABLE OF CONTENTS

Message from President/Chair of the Board ........................................... 2
Walking in the Footsteps of Giants ...................................................... 4
What Parallel Universe?: Kyle Mak, MBS ’12 and Andrew Vo, MBS ’13 .......... 8
Caregiver With An Edge: Jessica Costales, PPC ’12 ............................. 10
No ‘Bench Warmer’; Ramya Kartikeyan, PPM ’12 ................................. 11
TMP Presentations Hit A Record High! ................................................. 12
KGI Faculty and Admissions International Trips .................................. 16
KGI Partners With Chapman University for New School of BioPharmacy ....... 18
The History of Pharmacy & the History of Claremont Meet at KGI .......... 20
New Leaders Bring Vision, Energy to Board of Trustees ....................... 22
KGI Biomarker Research Center Receives $1.65 Million Grant ............. 24
KGI Receives Grant to Establish “Bridging The Gap” Summer Boot Camp .... 25
KGI Now Administering Professional Science Master’s Program Affiliation ... 26
BioPharmacy Advisory Board ......................................................... 27
Donors ........................................................................................................ 28
Leadership ............................................................................................ 32
Faculty ...................................................................................................... 34
Advisory Council .................................................................................... 36
Corporations and Foundations .............................................................. 38
Alumni Board ......................................................................................... 39
Financials ................................................................................................. 40
Being seated on stage at this year’s Commencement ceremony provided a view of the graduates and their families in the audience, a wonderful perspective of how much KGI has grown in little over a decade — both as a community and as an institution of higher education. This past spring, KGI graduated the largest class in its history with 92 new alumni, and in the fall we welcomed 97 new students, representing the largest class ever to be admitted. And, as impressive as that may be, it’s far from being the only milestone we’ve reached this year. Other accomplishments include:

- We achieved 100 percent participation by the Board of Trustees in the 2011-2012 Annual Fund campaign. This level of support by those who are tasked with guiding our institution will go a long way toward helping us meet future fundraising goals. Many foundations and grant-making bodies look to board participation as a key indicator of an organization’s strength and sustainability, so we are especially gratified at this show of support. In fact, Annual Fund participation increased across all constituencies this year, and we would like to thank everyone for their generous support.

- We set another record with Team Masters Projects (TMPs). On May 2, a record 19 projects were presented in two parallel sessions; 11 projects were from returning sponsors with eight companies sponsoring in consecutive years. Since its inception, KGI has completed 119 Team Masters Projects with repeat sponsors constituting 31 percent of those projects. The focus of TMPs ran the gamut from rare childhood diseases to next-generation medical devices to biofuels, and our students continued to impress sponsors with their professional abilities and creative insights. (pg. 12)

- As we continue to solidify our position as a leader in bioscience graduate education, the emphasis of our planning now shifts toward growing our “brand” and finding new opportunities for collaboration. Our goal is to manage our growth in a way that will bring the most benefit to our students and help us achieve our mission of utilizing the power of the life sciences for the benefit of society. This year, we have taken several significant steps toward achieving this type of “smart” growth.

A NATIONAL ROLE

KGI was selected by the Council of Graduate Schools (CGS) and the Alfred P. Sloan Foundation to administer the Professional Science Master’s (PSM) affiliation process, which plays an integral role in establishing and maintaining high-quality standards for PSM programs across the country. KGI launched the first PSM in the nation as part of a pioneering approach to educating technically proficient industry leaders of the future. The PSM has since been adopted by the graduate education community nationwide in an effort to produce the kinds of science and engineering professionals needed to keep the United States globally competitive. (pg. 26)

INTERNATIONAL OUTREACH

As KGI’s reputation as one of the world’s best training grounds for young scientists and biofinance entrepreneurs increases, the institute has stepped up international recruitment efforts and forged new partnerships. Last December, President Schuster made a two-week trip to India, accompanied by Karen Schneider, vice president for advancement, Marlene Singleton, director of alumni relations and the annual fund, and admissions recruiter Brandy Orlando. With stops in New Delhi, Bangalore, Mumbai and Hyderabad, the group made significant progress toward its goal of forging new partnerships, expanding student internship opportunities and recruiting new TMP sponsors. Also, this past spring, KGI was added to the Chinese Ministry of Education’s list of approved schools in California, and the institute signed a Memorandum of Understanding with China’s Zhongmei Group. The first two international TMPs will be conducted through the group in the 2012-2013 academic year. (pg. 16)

“THE SHOT FELT ‘ROUND THE WORLD”

As part of ongoing efforts to develop meaningful collaborations with top innovators and thinkers around the country, KGI partnered with the Jonas Salk Legacy Foundation to present an exclusive screening of “The Shot Felt ‘Round the World” on September 9 at the Huntington Library in San Marino. The documentary film about Jonas Salk and the nation’s crusade to develop the polio vaccine was accompanied by a panel discussion that included Jonas Salk’s sons, Drs. Peter and Jonathan Salk; Tjardus Greidanus, the film’s director-editor; and producer Laura Davis.

CHAPMAN-KGI SCHOOL OF BIOPHARMACY

In February, KGI signed a Memorandum of Understanding with Chapman University to establish a school of BioPharmacy. The school will reorient the Doctor of Pharmacy degree toward crucial developments in pharmacogenomics, and its vision will reflect the ways in which pharmacists are increasingly asked to shoulder a primary role in matching drugs or therapies to a particular patient or strain of illness, as well as translating their clinical expertise into drug discovery in industry. The school will open in fall of 2014, pending national accreditation, with classes initially being held on the KGI campus. (pg. 18)

THE 2012-2013 STRATEGIC PLAN

In order to ensure maximum effectiveness during this next phase of our growth, we have completed our second strategic plan which delineates institutional priorities. Of great importance is advancing KGI’s research prominence by investing in translational research activities; promoting active learning through integrative research experiences; and recruiting and retaining top-quality faculty active in both research and teaching.

Another of our top priorities is to deliver educational innovation on all levels. In order to ensure that we are meeting this goal, we will implement active learning strategies throughout our educational programs and invest in educational technology to support and expand our program portfolio. We will also create a professional development plan for our faculty that enables them to work effectively with students to ensure that they graduate with the highest level of professional skills and scientific knowledge. Finally, since we know that our ability to meet these goals depends on the entire KGI team, fostering a greater level of institutional continuity and community rounds out the list of our goals.

We know that you, too, are deeply invested in KGI’s success, and we will continue to update you on our progress as we expand our reach and form new partnerships, never losing sight of our mission. We thank you again for your support and counsel and look forward to hearing from you in the upcoming year.  

Robert E. Coffy, PhD
Chair of the Board

Sheldon M. Schuster, PhD
President
THE CAREERS AND LEGACIES OF THESE BIOTECH LEGENDS CONTINUE TO SHAPE KGI’S SUCCESS.

Arnold Beckman, George Rathmann and Art Riggs — this pioneering trio was not only instrumental in launching the biotechnology industry, but their entrepreneurial zeal, scientific pedigree and visionary leadership also embody the very spirit of KGI.

As a child, Beckman made toys by hand and fashioned a chemistry lab out of a family shed. Later, he invented a pH Meter, which is now used to monitor water quality, soil, sewer and waste disposal.

Rathmann earned the nickname “golden throat” for his persuasiveness in recruiting scientists and investors to back what would become two of the most successful drugs in history — Epogen, to treat anemia, and Neupogen, which helps ward off infection for cancer patients. Both were inspired by him formed the core of the life science industry and its many advances in the 20th century,” said KGI Trustee James Widergren, retired senior vice president for global customer operations at Beckman Coulter. “Dr. Beckman believed in the useful application of science which is a core of the KGI philosophy.”

Eventually, he recognized the device’s larger potential and established National Technical Laboratories. An essential tool in analytical chemistry, the pH Meter earned Beckman a place in the National Inventors Hall of Fame. His spectrophotometer vastly improved the time and accuracy of biological assays.

Beckman also provided the seed money to transistor inventor William Shockley, who helped turn Silicon Valley into a hotbed of innovation.

National Technical Laboratories became Beckman Industries and eventually Beckman Coulter, a world leader in scientific instrumentation. The company boasts a product line refined over decades, from electrical resistors, to radar equipment, to heart monitors, to liquid crystal digital displays.

Beckman was the recipient of the National Medal of Science, the National Medal of Technology and the Public Welfare Medal.

In 1989, he received the Presidential Citizens Medal from President Ronald Reagan, a friend whom Beckman encouraged to run for governor of California in 1966.

Beckman Coulter is a major supporter of KGI. The company sponsors TMPs, while company executives serve on KGI’s Board of Trustees and Advisory Council and participate in diagnostics workshops with students and faculty. In addition, retired Beckman Coulter executives and managers are now members of KGI’s faculty.

When Beckman invented the spectrophotometer, which helps ward off infection for cancer patients, he initially wanted to help a friend from the California Fruit Growers Association measure the acidity of lemon juice. Eventually, he recognized the device’s larger potential and established National Technical Laboratories. An essential tool in analytical chemistry, the pH Meter earned Beckman a place in the National Inventors Hall of Fame. His spectrophotometer vastly improved the time and accuracy of biological assays.

Beckman also provided the seed money to transistor inventor William Shockley, who helped turn Silicon Valley into a hotbed of innovation.

National Technical Laboratories became Beckman Industries and eventually Beckman Coulter, a world leader in scientific instrumentation. The company boasts a product line refined over decades, from electrical resistors, to radar equipment, to heart monitors, to liquid crystal digital displays.

Beckman was the recipient of the National Medal of Science, the National Medal of Technology and the Public Welfare Medal.

In 1989, he received the Presidential Citizens Medal from President Ronald Reagan, a friend whom Beckman encouraged to run for governor of California in 1966.

Beckman Coulter is a major supporter of KGI. The company sponsors TMPs, while company executives serve on KGI’s Board of Trustees and Advisory Council and participate in diagnostics workshops with students and faculty. In addition, retired Beckman Coulter executives and managers are now members of KGI’s faculty.

“Beckman, like other major players in the life sciences industry, valued KGI’s mission,” said Jim Osborne, CBR director, Robert E. Finning Professor of Applied Life Sciences and former corporate vice president of advanced technology at Beckman Coulter. “KGI is dependent on collaboration with industry to survive.”

After conducting research that led to the mass production of insulin, Riggs advanced to the upper echelons of medicine by applying his knowledge to the creation of baby wards.

Riggs is often considered the father of medical devices. The device found a new purpose in premature babies.

Arnold Beckman, George Rathmann and Art Riggs — this pioneering trio was not only instrumental in launching the biotechnology industry, but their entrepreneurial zeal, scientific pedigree and visionary leadership also embody the very spirit of KGI.

As a child, Beckman made toys by hand and fashioned a chemistry lab out of a family shed. Later, he invented a pH Meter, which is now used to monitor water quality, soil, sewer and waste disposal.

Rathmann earned the nickname “golden throat” for his persuasiveness in recruiting scientists and investors to back what would become two of the most successful drugs in history — Epogen, to treat anemia, and Neupogen, which helps ward off infection for cancer patients. Both were inspired by him formed the core of the life science industry and its many advances in the 20th century,” said KGI Trustee James Widergren, retired senior vice president for global customer operations at Beckman Coulter. “Dr. Beckman believed in the useful application of science which is a core of the KGI philosophy.”

Eventually, he recognized the device’s larger potential and established National Technical Laboratories. An essential tool in analytical chemistry, the pH Meter earned Beckman a place in the National Inventors Hall of Fame. His spectrophotometer vastly improved the time and accuracy of biological assays.

Beckman also provided the seed money to transistor inventor William Shockley, who helped turn Silicon Valley into a hotbed of innovation.

National Technical Laboratories became Beckman Industries and eventually Beckman Coulter, a world leader in scientific instrumentation. The company boasts a product line refined over decades, from electrical resistors, to radar equipment, to heart monitors, to liquid crystal digital displays.

Beckman was the recipient of the National Medal of Science, the National Medal of Technology and the Public Welfare Medal.

In 1989, he received the Presidential Citizens Medal from President Ronald Reagan, a friend whom Beckman encouraged to run for governor of California in 1966.

Beckman Coulter is a major supporter of KGI. The company sponsors TMPs, while company executives serve on KGI’s Board of Trustees and Advisory Council and participate in diagnostics workshops with students and faculty. In addition, retired Beckman Coulter executives and managers are now members of KGI’s faculty.

“Beckman, like other major players in the life sciences industry, valued KGI’s mission,” said Jim Osborne, CBR director, Robert E. Finning Professor of Applied Life Sciences and former corporate vice president of advanced technology at Beckman Coulter. “KGI is dependent on collaboration with industry to survive.”
Amgen was little more than a vague notion when Rathmann took over in 1980, at a time when only a handful of companies dabbled in genetic engineering.

In less than a decade, Rathmann, a former head of research and development for the diagnostics division of Abbott Laboratories, led Amgen through the successful development of Neupogen, which helps cancer patients receiving chemotherapy ward off infection, and Epogen, used to treat anemia. Before his death earlier this year, Rathmann received kidney dialysis and was treated with Epogen.

After stepping down as Amgen’s chief executive in 1990, Rathmann co-founded Icos, known for the erectile dysfunction drug, Cialis. He even convinced Microsoft founder Bill Gates to invest.

The KGI family and the Amgen family have enjoyed a fruitful relationship over the years. Bill Rich, vice president for Amgen’s international supply chain, is a member of KGI’s Advisory Council, while Daniel Vapnek, PhD, founding senior vice president of research, who is now retired from Amgen, serves as an advisor emeritus.

The Amgen Bioprocessing Center at KGI, founded in December 2004 thanks to a $2 million gift from The Amgen Foundation, serves as the backbone of the Bioprocessing Foundation, serves as the backbone of the Bioprocessing December 2004 thanks to a $2 million gift from The Amgen Foundation, serves as the backbone of the Bioprocessing Foundation, serves as the backbone of the Bioprocessing Foundation, serves as the backbone of the Bioprocessing Foundation, serves as the backbone of the...
In May, KGI graduated the largest class in its history. Like their predecessors, the 92 members of the Class of 2012 came to the institute from a number of different backgrounds and academic disciplines, but with a shared determination to build a career in the life sciences — one that will benefit society. Their enthusiasm is contagious, and a few minutes after you meet them, you don’t doubt that they’ll succeed.

WHAT PARALLEL UNIVERSE?:

KYLE MAK, MBS ’12 AND ANDREW VO, MBS ’13

In a parallel universe, the lives of Kyle Mak, MBS ’12, and Andrew “Drew” Vo, MBS ’13, might not be connected in any way. But, for the last few years at least, the similarities have been striking. When Mak graduated from KGI, he turned over the mantle of the MBS class presidency to Vo, and for a few weeks this summer their paths crossed again at the biotech giant Amgen, where Vo completed a summer internship and where Mak started his job as a supply chain manager.

“I was extremely excited when I got the offer from Amgen in March. I did my internship there last year and I thought it went great. So I hoped I’d be in a good position if there was an opportunity, but there’s never a guarantee you’re going back, especially in today’s economy,” said Mak, who is part of a team working to ensure operational excellence and reduce costs and inefficiencies in Amgen’s supply chain.

As far Vo, his time at Amgen this summer lived up to all his expectations. “I knew this would be my last chance to get involved in this way in an academic setting. Plus, I saw some areas, such as scheduling and communication between students and faculty and staff that I thought needed improvement and where I thought I could make a difference.”

As class president, Mak’s platform had three themes: building community, communication and culture.

“You have a wide mix of people at KGI, some are working professionals and some are coming straight from undergraduate school. Some people come from a more technical background, while others have more business or industry experience. But, it shouldn’t just be science versus business. It should be science and business. We’re not MBA’s. We are our own unique brand, and we can instill better communication between students and faculty and staff. As class president, I wanted to be in a position to make things better. My first year at KGI was pretty spectacular and I would definitely like to give back to the school.”

Mak says he was inspired to run for class president against tough competition from fellow classmates because he saw it as the best way to influence a community he had grown to love. “I knew this would be my last chance to get involved in this way in an academic setting. Plus, I saw some areas, such as scheduling and communication between students and faculty and staff that I thought needed improvement and where I thought I could make a difference.”

As class president, Mak’s platform had three themes: building community, communication and culture.

“After completing his first year at KGI and his own summer internship at Amgen, Mak made the decision to run for class president against tough competition from fellow classmates because he saw it as the best way to influence a community he had grown to love. “I knew this would be my last chance to get involved in this way in an academic setting. Plus, I saw some areas, such as scheduling and communication between students and faculty and staff that I thought needed improvement and where I thought I could make a difference.”

As class president, Mak’s platform had three themes: building community, communication and culture.

“A definition of a third culture kid is someone who is Americanized but assimilated into different cultures. Thats me. My best friends have always been of different races and religions, and that leads you to develop tolerance and a better cultural understanding.”

Like Mak, Vo intends to make enhancing culture and communication two of his top priorities as class president.

“At the beginning of last year, I told myself I wasn’t going to run,” he said, “but I’m not the type of person to settle. I wanted to be in a position to make things better. My first year at KGI was pretty spectacular and I would definitely like to give back to the school.”

Vo cites the many group projects as the most rewarding — and also the most challenging — aspect of the KGI experience. “Everyone always talks about the group projects for a reason,” he said. “I would definitely point to the project in Angielska Niemii’s Medical Diagnostics class as probably my biggest challenge and greatest learning experience so far. Our advisors admitted that we were dealt one of the most difficult hands in regards to groups and research topics, but my team and I found a way to accommodate all of this in order to be successful.”

Vo, who surprisingly describes himself as an introvert at heart, says he first learned about KGI when he had the opportunity to interview Amylin Pharmaceuticals CEO and KGI Trustee Dan Bradbury in an undergraduate bioengineering class at UCSD. “We discussed what it was like to be a CEO and the steps you have to take to get there. He mentioned KGI. At the time I was focused on working in industry right away, but it struck an interest in me,” said Vo, who traces his interest in biotechnology back to junior high school when his father introduced him to the subject of stem cell research after his great grandmother died as a result of hepatitis C.

“I really was impressed by what biotechnology could make possible, but after working in the lab for a few years, I knew this was not the right career path for me, at least not long term. By that time I knew I had an inclination for business,” he said, “and that’s why KGI clicked with me.”

After he graduates next May, Vo says he’d love to join Mak at Amgen and have the experience of working in a “really strong” biotechnology company. And, in the long term, Vo says he’s open to anything. “I’ve gotten great experience at KGI and at my Amgen internship. If I stay along this path, I feel that I could go off to any setting anywhere in the world and be able to make a significant contribution.”
During her undergrad years at UC Irvine, Jessica Costales, PPC ‘12, had a lot on her plate. The aspiring physician was working part time and taking care of her mother, Ofelia, who has chronic kidney disease and requires dialysis. Since she didn’t perform as well as she would’ve liked academically, Costales hoped to improve her chances of getting into medical school by completing a PostBaccalaureate Premedical Certificate (PPC) program. KGI’s program particularly attracted her because, unlike some other programs she had looked at, the curriculum didn’t mimic the first year of medical school.

“KGI seemed to offer a different set of classes than I could get anywhere else, and I wanted a chance to improve my grades and prove to medical school admissions that I could handle the work load,” said Costales, who is considering pursuing a career in emergency medicine or another “fast-paced” specialty.

Handling the workload at KGI and mastering its broad-based curriculum, which includes courses in pharmaceutical discovery and development and medical diagnostics and devices, wasn’t always easy, especially in the beginning. However, Costales thinks the knowledge and skills she has gained as a PPC student will be invaluable to her as a practicing physician.

“I’m very passionate about research, particularly bioprocessing, and I feel that I could integrate that into my career,” said Costales, who spent the summer interning with Dr. Ian Phillips at the Center for Rare Disease Therapies. There, she investigated microRNA regulation of the renin-angiotensin system (RAS), which is a hormone system involved in controlling blood pressure, fluid and electrolyte homeostasis.

“Working in the biotechnology industry, you’re helping a large number of people and that’s the most important thing to me in a career,” she said.

Things tend to move pretty quickly for Ramya Kartikeyan, PPM ‘12. The Bahrain-native recently started a new job as a senior health care analyst for infectious disease in GlobalData’s Boston office. The company provides clients access to business intelligence on the pharmaceutical, medical device and biotech industries, and Kartikeyan says she’s happy to be back in one of her old East Coast stomping grounds.

“I hate it when people use the expression, ‘it just fell into my lap,’ but that is sort of what happened with this job,” she said. “I ran into a friend at lunch. He told me about the job and encouraged me to email him my résumé.

The whole interview process, which included a written assessment test and several interviews, including a final one with the director of operations, took about a week from start to finish.”

The same held true for her decision to apply to KGI. After earning her PhD in biochemistry and molecular biology at Penn State University, she knew she wanted to further her education in business and was considering getting an MBA at Cornell’s Johnson Graduate School of Management. But, after reading about KGI in a magazine, she decided it might be the perfect fit for her — especially since she was set on a career in biotechnology and health care.

In fact, KGI’s industrial and management education in business and was considering getting an MBA at Cornell’s Johnson Graduate School of Management. But, after reading about KGI in a magazine, she decided it might be the perfect fit for her — especially since she was set on a career in biotechnology and health care.

“[At KGI] you get an in-depth understanding of the industries that will support your work as a physician when making diagnoses, you will understand how test results are generated. They don’t just magically appear.”

“"Working in the biotechnology industry, you’re helping a large number of people and that’s the most important thing to me in a career,” she said.

In fact, Costales developed such an interest in the biotech industry at KGI that she’s continuing on in the MBS program and is hoping to work on a TMP that allows her to expand her knowledge of bioprocessing.

“I’m very passionate about research, particularly bioprocessing, and I feel that I could integrate that into my career,” said Costales, who spent the summer interning with Dr. Ian Phillips at the Center for Rare Disease Therapies. There, she investigated microRNA regulation of the renin-angiotensin system (RAS), which is a hormone system involved in controlling blood pressure, fluid and electrolyte homeostasis.

The same held true for her decision to apply to KGI. After earning her PhD in biochemistry and molecular biology at Penn State University, she knew she wanted to further her education in business and was considering getting an MBA at Cornell’s Johnson Graduate School of Management. But, after reading about KGI in a magazine, she decided it might be the perfect fit for her — especially since she was set on a career in biotechnology and health care.

In fact, KGI’s industrial and management education in business and was considering getting an MBA at Cornell’s Johnson Graduate School of Management. But, after reading about KGI in a magazine, she decided it might be the perfect fit for her — especially since she was set on a career in biotechnology and health care.

“[At KGI] you get an in-depth understanding of the industries that will support your work as a physician when making diagnoses, you will understand how test results are generated. They don’t just magically appear.”

"Working in the biotechnology industry, you’re helping a large number of people and that’s the most important thing to me in a career,” she said.
"Having the opportunity to really sit down and talk with some of the most creative people in the world, including a Nobel Prize nominee, was something I'll never forget and something I never thought I'd be able to do at this stage of my career," said Cijian Feng, MBS '12, who was part of the Eli Lilly TMP on pharmaceutical R&D transformation through innovation.

The team focused on the structural, cultural and behavioral elements that are necessary to sustain successful innovation across several R&D intensive industries, including agricultural biotechnology, oil & gas and pharmaceuticals. In order to get essential data for their inquiry, they partnered with the Industrial Research Institute (IRI), a non-profit organization which brings together leaders from diverse industries in an effort to enhance the effectiveness of technological innovation. More than 200 companies in the U.S. are members of the IRI.

Not only did Feng and his Lilly teammates, Ryan McComb, Durgalaxmi Ramachandhiramani and Selena Gunggavakin, participate in TMP presentations, but they also discussed the results of their nine-month study of how to improve corporate innovation during the IRI's annual meeting held on May 7 in Indian Wells, a desert resort near Palm Springs.

"By leveraging the competitive advantage of having an unbiased view towards R&D innovation, we were able to provide credible insights to the IRI audience," said Ramachandhiramani. "What's more, I think we were also able to prove that graduate student consultants are equally capable of finding solutions to different organizational challenges in innovation."

The Eli Lilly team was not the only one on the move this year; the Sigma-Tau-sponsored team traveled to Boston for the 2012 BIO International Convention on behalf of KGI's Center for Rare Disease Therapies. The team, consisting of Lauren Breslin, Abimbola Onikoro, Laurett Rivera and Hrishikesh Thakur, participated in breakout sessions in conjunction with the convention's Orphan Disease Forum, which included topics such as "Succeeding in Rare Diseases: A Collaborative Approach" and "Rare Diseases: Orphaned but Not Alone."

"I especially enjoyed listening to top executives comment on potential business models for orphan disease therapies during the convention’s Orphan Disease Forum," Breslin said. "One panelist mentioned the importance of patient involvement and social media to rare disease research, which was a critical element in my team’s project this past year."

Focusing on economics, the Sigma-Tau group took on the complex challenge of examining the direct, indirect and intangible costs associated with Necrotizing Enterocolitis (NEC), a devastating gastrointestinal disease that primarily affects prematurely born newborns. The group utilized social media to evaluate the intangible costs which include the emotional and social impact that NEC has on survivors, family members and caregivers.

"Our outreach and communications with NEC families was an amazing component of this project and was an unforgettable experience for me personally," Breslin said. "We spoke with mothers who had experienced many parents’ worst fear, watching your baby fight for his or her

**TMP PRESENTATIONS HIT A RECORD HIGH!**

*From rare childhood diseases to next-generation medical devices to biofuels, the 2011-2012 Team Masters Projects increased in both size and scope.*
Our outreach and communications with NEC families was an amazing component of this project and was an unforgettable experience for me personally.”

- Lauren Breslin, MBS '12

The trauma and devastation of this experience has motivated many of these families to fight for research and promote awareness, and because of that they were willing and excited to speak with us.”

The 2011-2012 Team Masters Project presentations were the most varied and numerous in KGI’s history, according to TMP Director Craig Adams. “Several teams were involved in developing algorithms to help guide strategic R & D activities toward targeted diseases, while other teams carried out marketing research on highly technical products and provided sponsors with reports and databases that will be used as they develop their next-generation products,” Adams said, adding that “regardless of the subject matter, the quality of each team’s output was truly stunning.”

Abbot Medical Optics (AMO) tasked students Josh Miller, Gloria Lin, John Weaver and Joy Wong with developing a working prototype of a next-generation remote control device used in intraocular lens replacement surgery. When creating the prototype, the group focused on the human factors required for optimal functioning of the device and actively sought feedback from current users of the device.

“AMO executives actually took our prototype design to countries such as India and China and let the OR nurses handle it,” Miller said. “We found that there was definitely a difference in usage in developed and developing countries. Here in the U.S. the device probably will sit on a tray and not move much, but in developing countries it’s more likely to get moved around and dropped. So it has to be able to stand up to all that.”

Reaching outside of the medical and pharmaceutical industries, the group sponsored by Clear Springs Land Company analyzed the feasibility of building an open-pond algae farm on 18,000 acres of land the company owns in Bartow, Florida. The biofuels industry is a potentially huge market, but one that requires hundreds of millions in investment in unproven technology to compete with commodity oil prices. The KGI team’s final report evaluated the commercialization potential of these byproducts and provided recommendations for the most profitable options.

“Since its founding, KGI has always taken the approach that working closely with industry would not only give our students the best education, but also would help us to fulfill our mission of utilizing the power of the life sciences for the benefit of society,” KGI President Sheldon Schuster said. “There is no better example of that collaboration than the Team Masters Projects, which increase in size and scope every year. In fact, this year, our first two international TMPs will be conducted through the Zhongmei Group in China.”
Jim Osborne, Robert E. Finnigan Professor of Applied Life Sciences and Director of the Center for Biomarker Research, visited Dr. Andreas Meinitzer in Zederhaus to consult on new diagnostic biomarkers for monitoring patients with type 2 diabetes and chronic kidney disease.

Jim Sterling, VP of Academic Affairs and Dean of Faculty, attended the 8th International Meeting on Electrowetting in Athens accompanied by CGU PhD student Michael Franklin. Sterling also co-directs the Microfluidics Research Laboratory at KGI along with Dr. Ali Nadim.

On a trip through Asia sponsored by Millipore Corporation, Matt Croughan, George B. and Joy Rathmann Professor and Director of the Amgen Bioprocessing Center, lectured on “Best Practices to Improve Cell Culture Titers” at the 2012 Global Biopharma Technology Policy Forum in Seoul.

Jim West, professor, innovation & entrepreneurship, gave a keynote talk titled, “Strategic Openness: the Solution to an Open Strategy for Competitive Advantage” at the International and Political Economy Group conference at the University of the Witwatersrand, Johannesburg.

Ian Phillips, Norris Professor of Applied Life Sciences and Director of the Center for Rare Disease Therapies, spoke at a molecular biology conference at Universidade de São Paulo. He also collaborates with a KGI faculty member on stem cell and cardiovascular research.

In December, KGI President Sheldon Schuster took a two-week trip to India that included stops in New Delhi, Bangalore, Mumbai, and Hyderabad. The goal was to forge new partnerships, expand student internship opportunities, and recruit new sponsors for the TMP program.

Dr. West taught a PhD seminar on open innovation and gave a lecture on his solar research at RWTH Aachen University and was the opening speaker at a meeting of a German-Dutch-Belgian regional economic development effort based in Aachen.

Ian Phillips, Norris Professor of Applied Life Sciences and Director of the Center for Rare Disease Therapies, spoke at a molecular biology conference at Universidade de São Paulo. He also collaborates with a KGI faculty member on stem cell and cardiovascular research.
KGI has partnered with Chapman University to establish a joint School of BioPharmacy, which will open in the fall of 2014, pending national accreditation. The new Chapman-KGI School of BioPharmacy will focus on preparing graduate pharmacists for professions in biotechnology and the pharmaceutical industry as well as for modern pharmacy practice. KGI has been planning for the school, which will add to its reputation as a leader in life science education, for more than two years, and it found the perfect partner in Chapman.

“This collaboration is a remarkable opportunity,” said James L. Dott, president of Chapman University. “It builds on KGI’s innovative professional master’s and postdoctoral programs and close biotechnology and pharmaceutical industry ties, and takes advantage of Chapman’s strengths in computational sciences and entrepreneurship.”

The school will reorient the Doctor of Pharmacy degree toward crucial developments in pharmacogenomics, including the growth of personalized medicine, the delivery of biomolecules, changes in drug and device development, and progress in clinical trials and team-based operating environments. Its vision reflects the ways in which pharmacists are increasingly asked to shoulder a primary role in matching drugs and therapies to a particular patient or strain of illness, as well as translating their clinical expertise into drug discovery in industry.

“The Chapman-KGI School of BioPharmacy will embrace this change in the profession,” said KGI President Sheldon Schuster. “Current advances in genomics and the growing convergence of drug discovery, diagnostics and medical devices are creating new opportunities for pharmacists in the life science industry and modern clinical practice. This new school will help prepare highly qualified individuals to take advantage of those opportunities.”

Kathy D. Webster, PharmD, PhD, has been hired as interim dean and will help guide the school through the accreditation process. Dr. Webster has extensive experience helping to establish and working with new schools of pharmacy, including the University of Maryland Eastern Shore School of Pharmacy, where she recently served as professor and associate dean of academic affairs. Previously, she was the assistant dean and chair of pharmaceutical sciences and a professor at Feik School of Pharmacy, University of Incarnate Word in San Antonio, Texas. She also held several positions at Campbell University in Buies Creek, North Carolina, including director of science education outreach, director of the pharmaceutical analytics laboratory and associate and assistant professor of medicinal chemistry. As head of the analytical section there, she helped found and develop the Campbell University Pharmaceutical Sciences Institute (CUPSI), which provides contract services to small local and regional pharmaceutical companies. She holds a Doctor of Pharmacy from the University of the Pacific in Stockton, California, and a PhD in medicinal chemistry from the University of Minnesota, Minneapolis.

“The talents and resources possessed by KGI and Chapman, as well as their biopharmaceutical and clinical partners, provide an opportunity to push the education of future pharmacists to a new level,” Webster said. “I’m very happy to be a part of this truly unique, challenging and exciting endeavor.”

Classes will initially be held on the KGI campus, while Chapman pursues construction of a 120,000-square-foot Science Center in the City of Orange. The new Science Center will house Chapman’s portion of the School of BioPharmacy and the university’s Schmid College of Science and Technology. KGI is planning a major capital campaign that will expand facilities for ongoing teaching, research programs and the Chapman-KGI School of BioPharmacy, which is expected to grow to a full enrollment of 320 students in the four-year PharmD program. This fundraising initiative was given a major boost in March when KGI Trustee Art Riggs and his wife Jane made a $1 million gift to the school.

“This generous gift gives us a solid foundation from which to build and energizes our fundraising efforts as we prepare for the upcoming capital campaign,” Schuster said. “Graduates of the Chapman-KGI School of BioPharmacy are going to be ahead of the curve and well equipped to make a significant contribution to the health care field. The more people that learn about the school’s mission, the more they will share in our enthusiasm for it going forward.”

KGI PARTNERS WITH CHAPMAN UNIVERSITY FOR NEW SCHOOL OF BIOPHARMACY

Innovative school set to open in 2014, interim dean hired

KGI - Annual Report 2011-2012

18
NEW LEADERS BRING VISION, ENERGY TO BOARD OF TRUSTEES

The KGI Board of Trustees elected five new members in 2011-2012: Frank Biondi, Joann DiGennaro, Gregg Lapointe, Maxine Savitz and Martha Vincent. They bring with them a rich pool of industry expertise, innovative thinking and creative energy from which the institute can draw upon as it continues to grow and fulfill its mission.

Joann DiGennaro
President, Center for Excellence in Education
> Elected March 2012
Joann DiGennaro established the Center for Excellence in Education (CEE) with an investment advisory firm concentrating in media, since 1999. From 1996 through 1998, he was chairman and CEO of Universal Studios and a member of the board of directors of Seagram. From 1987 until 1996, he was president and CEO of Viacom Inc. and a member of the board of directors of Viacom. From 1985 through 1987, he was chairman and CEO of Coca-Cola Television and an executive vice president of the Entertainment Business Sector of the Coca-Cola Company. From 1978 through 1984, he was chairman and CEO of Home Box Office and a vice president of its parent company, Time Inc. (now Time Warner).

President George W. Bush appointed him to the U.S. Army War College Board of Trustees where he served as the first female chairperson of that board. He also was appointed to the Advisory Council (the Board) of the National Aeronautics and Space Administration (NASA).

DiGennaro holds a Bachelor of Science from Purdue University and a Master of Science from the University of Maryland. She read the law at Oxford University and received her Juris Doctorate from George Mason University. She was a research affiliate at Harvard University in the Program for Information Policy Resources and is the author of “Scholarships and Fellowships for Math and Science Students and Science Literacy: Essential for Decision Making.”

Frank J. Biondi, Jr.
Senior Managing Director, WaterView Advisors
> Elected December 2011
Frank Biondi has been senior managing director of WaterView Advisors concentrating in media, since 1999. From 1996 through 1998, he was chairman and CEO of Universal Studios and a member of the board of directors of Seagram. From 1987 until 1996, he was president and CEO of Viacom Inc. and a member of the board of directors of Viacom. From 1985 through 1987, he was chairman and CEO of Coca-Cola Television and an executive vice president of the Entertainment Business Sector of the Coca-Cola Company. From 1978 through 1984, he was chairman and CEO of Home Box Office and a vice president of its parent company, Time Inc. (now Time Warner).

Prior to that, Biondi had positions at AERST, a division of American Home Products, and with New Jersey Medical School, Department of Pharmacology.

She is a Fellow of the American College of Clinical Pharmacology and has received several awards including the Israel Cancer Research Fund Award — Women of Achievement and Leadership America. Vincent received a BSc in biology and education from Iowa State University, and a PhD in pharmacology from the University of Medicine and Dentistry of New Jersey. She did her postdoctoral work at Thomas Jefferson University, in Philadelphia. She has authored more than 40 scientific publications in major journals.

Gregg Lapointe
Former CEO, Sigma-Tau Pharmaceuticals
> Elected June 2012
Gregg Lapointe, whose background includes extensive experience in the areas of biopharmaceutical global strategic planning as well as business development and corporate finance, led the transformation of Sigma-Tau Pharmaceuticals from a small specialty dialysis company into a global leader in the field of rare disease medicines with a diversified product portfolio. He also served the company as chief operating officer from 2003 to 2007 and as vice president, finance, from 2001 to 2002.

He serves on the board of directors of Sciclane Pharmaceuticals, Inc., and Saligenix, Inc., and is a member of the Corporate Council of the National Organization for Rare Disorders (NORD). He previously served on the boards of Quark Pharmaceuticals, Inc., and the Pharmaceutical Research and Manufacturers of America (PhRMA). He received a Bachelor of Arts in commerce from Concordia University in Montreal, Canada, a graduate diploma in accounting from McGill University and a Master of Business Administration from the Fuqua School of Business at Duke University. He is a Certified Public Accountant in the state of Illinois and a Chartered Accountant in Ontario, Canada.

Maxine Savitz
Vice President, National Academy of Engineering
> Elected June 2012
Dr. Savitz recently retired as the general manager for technology development at Honeywell, where she oversaw the development and manufacturing of innovative materials for the aerospace, transportation and industrial sectors. Prior to joining the company, she served in the capacity of deputy assistant secretary for conservation at the Department of Energy from 1979 to 1983.

She is a member of advisory boards at Sandia and Pacific Northwest National Laboratories and JPL. She is also a member of the board of directors of the American Council for an Energy Efficient Economy and the Federation of American Scientists. She is vice president of the National Academy of Engineering and a Fellow of the California Council on Science and Technology. Savitz was appointed to the President’s Council of Advisors for Science and Technology in 2009.

Savitz is also a member of the advisory group for the Department of Energy’s Fuel to Sunlight HUB at Caltech and was recently appointed to the Department of Energy, Energy Efficiency and Renewable Energy advisory board. She holds a PhD in chemistry from the Massachusetts Institute of Technology and a Bachelor of Arts in chemistry from Bryn Mawr College in Philadelphia.
KGI BIOMARKER RESEARCH CENTER RECEIVES $1.65 MILLION GRANT

KGI has received one of the largest contributions in its history, a $1.65 million grant from the Beckman Coulter Foundation. The check was presented by Beckman Coulter Foundation President Dr. Russell Bell to KGI President Sheldon Schuster and Dr. James Osborne in March, as the Board of Directors of the foundation were hosted at the KGI campus to conduct their quarterly board meeting.

The funding will go toward expansion of the Center for Biomarker Research (CBR), one of KGI’s top research laboratories, and the expansion of its Science Heritage Center, a historical exhibit of groundbreaking medical and research instruments.

CBR is focused on translational research to help patients and the medical community better manage Hereditary Inclusion Body Myopathy and Behçet’s Disease. Center director James Osborne explains, “This generous gift from the Beckman Coulter Foundation will allow us to increase laboratory personnel and expand research on diagnostic biomarkers to other rare diseases.”

These funds will also permit KGI to expand the Science Heritage Center exhibits to more fully display historical advances across the landscape of science, establish KGI’s first fellowships for a PhD and a postdoctoral student and enable highly motivated undergraduate students to participate in research. These students would in turn greatly increase the capabilities of CBR in the discovery and development of better diagnostic biomarkers for rare diseases.

“By investing in the students of KGI, we assure the world will have more well-trained biomedical professionals who no doubt will make outstanding contributions to society in their careers,” Bell said.

President Schuster noted that the Fellowship support would enable the most talented students from top schools, who might not otherwise have the resources to continue their education at KGI, to pursue applied research to improve health care outcomes in terms of patient well-being and a lower cost of care.

“We look forward to welcoming Beckman Coulter Fellows from among the most talented scientists in the nation, and educating them to shape the future of global health,” he said, adding that KGI is also well positioned to educate children and young adults about the importance of science, spark interest in careers in the life sciences and honor the tremendous contributions of Dr. Arnold Beckman through the expansion of the Science Heritage Center exhibits.

KGI RECEIVES GRANT TO ESTABLISH ‘BRIDGING THE GAP’ SUMMER BOOT CAMP

KGI has received a $49,950 grant to support “Bridging the Gap” Summer Boot Camp from the Burroughs Wellcome Fund, an independent private foundation dedicated to advancing the biomedical sciences by supporting research and other scientific and educational activities. The 12-day intensive program will provide PhD students and post-doctoral scientists an introduction to the transferable skills and industry experiences not afforded during graduate studies but that are required to obtain positions in the life science industries. The program will be directed by Steve Casper, Henny Riggs Professional Management and associate dean for faculty development.

This model graduate program will be a groundbreaking effort that integrates classroom-centered active learning and professional development/networking opportunities with hands-on experience working on a team-based industrial science project. It will provide boot camp participants with basic science-based industry skills, insights into the organizational structure of the life science industries, an overview of available life science career options, and an understanding of how to leverage PhD-level skills to transition into career positions in industry.

Boat camp participants will attend a series of introductory seminars in bioscience industry management, take part in professional development management workshops, and complete a team project focused on commercialization processes. Additional opportunities afforded will include basic science communication and writing skills, site visits to major life science firms and networking opportunities with life science professionals representing a broad range of backgrounds and life science industries.

“We are delighted to have won a grant from this highly competitive competition. The program will fund stipends for up to 60 PhD students and Postdoctoral Research Fellows to spend two weeks at KGI learning about bioscience management at a modest cost of approximately $800 per participant,” Casper said. “This is a first of its kind program that will showcase KGI’s excellence in providing management training for scientists and will also support recruiting efforts for our Postdoctoral Professional Masters Program.”

KGI CELEBRATES THE INTERSECTION OF SCIENCE AND ART

Last fall, Clementon artist and gallery owner Barbara Beretich donated a Jonas Salk bas-relief to KGI to commemorate the institute’s extensive work in disease research. Beretich presented her work at a branch attended by KGI staff, faculty and supporters. Also, in attendance was Dr. Peter Salik, the eldest son of Jonas Salk, who discussed his father’s legacy and the future of disease research.

PRESIDENT’S COUNCIL FORMED

In February, the Board of Trustees approved the formation of KGI’s first president’s council. Comprised of an elite group of life science industry leaders, the council will serve as confidential advisors to the president and the board Council members also will provide the institute with their knowledge, guidance and industry expertise as KGI strives to prepare graduates and pursue research that impacts the future of the biotechnology and health care industries. Although not responsible for governance of the institute or the implementation of plans, individual members will be contacted periodically by the president for advice and reactions to specific issues and pending decisions. Members of the inaugural council will include James Cattaneo, Dr. Michael Friedman, Marjorie Harris, Dr. Peter Salik and David Walt, PhD.
KGI NOW ADMINISTERING PROFESSIONAL SCIENCE MASTER’S PROGRAM AFFILIATION

In January, KGI was selected by the Council of Graduate Schools (CGS) and the Alfred P. Sloan Foundation to administer the Professional Science Master’s (PSM) Affiliation process, an integral part of establishing and maintaining the high-quality standards for PSM programs across the country.

KGI launched the first PSM, the Master of Bioscience, as its flagship program in a pioneering approach to educating technically proficient industry leaders. Since its beginning, the PSM has been adopted by the graduate education community nationwide in an effort to produce the kinds of science and engineering professionals needed to keep the United States globally competitive.

Over the years, the Sloan Foundation has worked with the CGS to institutionalize and promote the PSM degree. Based on the CGS-Sloan efforts, a robust system of managing the PSM Affiliation process and a PSM-specific website have been developed.

“We assumed responsibility for the program in July and have established a PSM office at KGI that we believe will add substantial value in building awareness, reputation, and corporate sponsorships for the PSM movement,” said Jim Sterling, VP for academic affairs and dean of faculty. Lindsay Janssen is serving as the PSM office manager; Marc Salata, KGI’s director of marketing, will assist with branding and marketing of the PSM movement; and Diana Bartlett, AVP and director of corporate partnerships, will help to identify ways that KGI’s outstanding corporate network can promote and advance the PSM movement among employers of PSM graduates.

CHAPMAN / KGI SCHOOL OF BIOPHARMACY ADVISORY BOARD

DON BAILEY, MBA
President & CEO, Questcor Pharmaceuticals

DAVID BECKER, PhD
Chief scientific officer for Pathway Genomics

DANIEL BRADBURY, B. Pharm, DMS
KGI trustee and CEO of Amylin Pharmaceuticals

GAYLE BRAZEAU, PhD
Dean of the University of New England College of Pharmacy

ANTHONY CARACCIOLI, B. Pharm
KGI trustee and retired senior vice president of manufacturing and operations for Gilead Sciences

PETER CLAGETT
Vice president of pharmaceutical strategies for WellPoint

STEPHEN ECK, MD, PhD
Vice president of oncology for Astellas Global Pharma Development

FELIX FRUEH, PhD
Former president of Medco Research Institute for Medco Health Solutions

SEAN GALLAGHER, PhD
KGI Advisory Council member and vice president and chief technology officer for UVP

JEFFREY HATFIELD, PharmD, MBA
President and CEO of Vitae Pharmaceuticals

JEFF HUGHES, PhD
Former research leader for Roche

GREGG LAPONTE, MBA
KGI trustee and former CEO of Sigma-Tau Pharmaceuticals

JOHN MAGUIRE, PhD
Claremont Graduate University President emeritus

LOUIS MARTINELLI, PhD, PharmD
Board chair for the Institute for Safe Medication Practices; former dean of Creighton University School of Pharmacy and Health Professions and the University of Pacific Thomas J. Long School of Pharmacy and Health Sciences

JEFF MASON, MD
Senior medical director for United Health Care

ALAN ROTHFIELD, MD
KGI adjunct professor; vice president of medical quality for Hollywood Presbyterian Medical Center, chief medical officer for Queen’sCare Family Clinics and adjunct professor of clinical pharmacology for USC Keck School of Medicine

GEORGE SAVAGE, MD, MBA
KGI Advisory Council member and chief medical officer for Proteus Biomedical

MARYLIN STANDIFER SHREEVE, RPh
President of Tailored Interactive Patient Health

PATRICK SINKO, PhD
Associate vice president for research at Rutgers University

DAVID SWENSON, RPh
Vice president of marketing and product management for CareFusion

RUSSELL TEAGARDEN, B. Pharm, PhD
Former vice president of clinical practices and therapeutics for Medco Health Solutions and associate dean for research at the Medco School of Pharmacy, Fairleigh Dickinson University

CURTIS TYREE, PhD
Vice president of operations for HUYA Bioscience International

GEORGE SAVAGE, MD, MBA
KGI Advisory Council member and chief medical officer for Proteus Biomedical

MARYLIN STANDIFER SHREEVE, RPh
President of Tailored Interactive Patient Health

PATRICK SINKO, PhD
Associate vice president for research at Rutgers University

DAVID SWENSON, RPh
Vice president of marketing and product management for CareFusion

RUSSELL TEAGARDEN, B. Pharm, PhD
Former vice president of clinical practices and therapeutics for Medco Health Solutions and associate dean for research at the Medco School of Pharmacy, Fairleigh Dickinson University

CURTIS TYREE, PhD
Vice president of operations for HUYA Bioscience International
KGI would like to thank all of our donors for their support in 2011 – 2012. Your generosity has helped further KGI’s mission to educate the future leaders of the applied life sciences.

FOUNDER’S CIRCLE ($1,000,000 AND ABOVE)
- Beckman Coulter Foundation
- Art and Jane Riggs

PRESIDENT’S CIRCLE ($250,000 - $499,999) - Anonymous

DEAN’S CIRCLE ($100,000 - $249,999)
- Mr. and Mrs. James M. Cornelius

LEADERSHIP CIRCLE ($50,000 - $99,999) - Astellas USA Foundation
- Dennis and Linda Fenton

PATRON’S CIRCLE ($25,000-$49,000) - Catherine and Francis Burzik Foundation
- Gensler Foundation
- The Sidney J. Weinberg, Jr. Foundation

STEWARDS’ CIRCLE ($10,000-$24,999) - Bristol-Myers Squibb Company
- California Technology Ventures, LLC
- Robert E. and Winifred B. Curry Foundation
- Fidelity Investments Charitable Gift Fund
- Gilead Sciences, Inc.
- John D. Baldeschwieler and Marlene R. Kannar Foundation
- Sheldon M. Schuster

- The Ralph M. Parsons Foundation
- The Steve and Bonnie Andersen Gift Foundation
- Mona and Murri Taleney
- James and Denise Widergren

AMBASSADOR’S CIRCLE ($5,000-$9,999) - Karen Bernstein and David Flores
- Judith Haybey
- The Ann Peppers Foundation
- Ian Phillips and Blanca Aguiar
- Jack and Gayle Riggs
- Jack and Jill Stark
- The H. Russell Smith Foundation
- Robert and Janet Tranquada

FELLOW’S CIRCLE ($1,000-$4,999) - Astra Foundation, Inc.
- Allergan Foundation
- Frank and Carol Bondi
- Lawrence and Tziyue Bookman
- James and Jeanne Cregg
- Joann DiGennaro
- Donna and Huang DiRocco (Parent ’09)
- Robert and Bette Finnigan
- John and Christie Glanville
- Ross Grossman
- Michael and Annia Harvey (Parent ’12)
- Bonnie Busenberg and Thomas Hellwell
- Peter Barton Hutt
- Bernard Kury
- Greg Lapointe
- Kenneth Linak
- Roger Marchetti
- Rodney Martin
- Alan Mendelsohn
- Arzu and Jim Osborne
- Stanford and Betsy Phelps
- Prudential Foundation
- Simon Rama
- Maxine Savitz
- Brandon and Marlene Singleton
- James Sterling and Shenda Baker
- Mark Stevenson
- Russell Teagarden
- Samuel and Justina Tsai (Parent ’12)
- Martha Vincent
- Richmond Wal
- Karen and Donald Wong (Parent ’12)
- Elizabeth Wright
- Lilian Wu
- Steven and Loura Yungshans (Parent ’10)

ASSOCIATE’S CIRCLE ($500-$999) - David Adelman
- Argen Foundation
- AT&T Foundation
- Robert Caraghar
- Linda Castle
- Matthew and Kathy Coughran
- Marc (MBS ’02) and Jean (Falzone) Dobie (MBS ’02)
- Mel and Jane Esselman (Parent ’10)
- Sean Gallagher
- Thomas and Elizabeth Garrow
- Paul and Christina Grint
- Hathaway Dinwiddie
- Dennis Huang
- Alice Kane
- Vanessa King
- Claudia Lee (PPM ’11)
- Brenda Mann
- Marlene and Brandon Singleton
- W.M. Keck Foundation

FRIEND’S CIRCLE ($1-$499) - Sahil Abdullah (MBS ’05)
- Adelameri Alandiga (MBS ’12)
- Raunakk Advani (MBS ’10)
- Pratik Ahuja (MBS ’10)
- Susan Alis (MBS ’12)
- Louise and Curt Arhile (Parent ’10)
- Sarah Arliken (MBS ’10)
- Padma and Sudhir (Pardiwala) Arunachalam (MBS ’10)
- Sandy Asayong (MBS ’02)
- Matthew Avila (MBS ’12)
- Kevin Baker (PPM ’12)
- Lorenzo Bensoud
- Vinyon Benzon (MBS ’11)
- Diana Barlett
- Amit Barva (MBS ’03)
- Tilak Bavkar (MBS ’05)
- Monandna Bhahroa (MBS ’09)
- Sahil Bakhoushe (MBS ’05)
- Victor Bhattacharjee (MBS ’12)
- Khush办理 Bhaviana (MBS ’11)
- Lilane and Louis Yungshans (Parent ’10)
- Xi Dang (MBS ’06)
- Joshua Der (MBS ’02)
- Eureka Dias (MBS ’08)
- Thomas DiRocco (MBS ’09)
- Vincent Eng (MBS ’07)
- Tim and Barbara Erwin
- Citian Feng (MBS ’12)
- Brian Feth (MBS ’05)
- Janelle and John Fluharty (MBS ’06)
- Yvonne Frame
- Susan Friedman
- Weaver Gaines
- Jessica Garcia
- Robert Garrahy
- Omar Goya (MBS ’04)
- Maria George (MBS ’09)
- Pratyusha Ghoshal (MBS ’12)
- Harold and Sandy Goldberg (Parent ’10)
- Jeffrey Grabley (MBS ’02)
- Larry Grill
- Mary Jo Gracia
- Matt Grzesik (MBS ’05)
- Alice Han (Parent ’10)
- Angella Cassey
- Sara and Wade Crow (MBS ’03)
- Jessica and Michael Cummings (MBS ’12)
- Milan Dalal (MBS ’12)
- Polina Datsyna (MBS ’06)
- Andrew Daugherty (MBS ’09)
- Brad Davis (MBS ’11)
- Ryan Davis
- Michael DeGiorgio (Parent ’12)
- Judy Marie DeGiorgio (Parent ’12)
- Marcus and Kristina DeMaster (MBS ’12)
- Fran Dang (MBS ’06)
- Richard Der Jr (MBS ’12)
- Eureka Dias (MBS ’08)
- Thomas DiRocco (MBS ’09)
- Vincent Eng (MBS ’07)
- Tim and Barbara Erwin
- Citian Feng (MBS ’12)
- Brian Feth (MBS ’05)
- Janelle and John Fluharty (MBS ’06)
- Yvonne Frame
- Susan Friedman
- Weaver Gaines
- Jessica Garcia
- Robert Garrahy
- Omar Goya (MBS ’04)
- Maria George (MBS ’09)
- Pratyusha Ghoshal (MBS ’12)
- Harold and Sandy Goldberg (Parent ’10)
- Jeffrey Grabley (MBS ’02)
- Larry Grill
- Mary Jo Gracia
- Matt Grzesik (MBS ’05)
- Alice Han (Parent ’10)
- Angella Cassey
- Sara and Wade Crow (MBS ’03)
- Jessica and Michael Cummings (MBS ’12)
- Milan Dalal (MBS ’12)
- Polina Datsyna (MBS ’06)
- Andrew Daugherty (MBS ’09)
- Brad Davis (MBS ’11)
- Ryan Davis
- Michael DeGiorgio (Parent ’12)
- Judy Marie DeGiorgio (Parent ’12)
- Marcus and Kristina DeMaster (MBS ’12)
- Fran Dang (MBS ’06)
- Richard Der Jr (MBS ’12)
- Eureka Dias (MBS ’08)
- Thomas DiRocco (MBS ’09)
- Vincent Eng (MBS ’07)
- Tim and Barbara Erwin
- Citian Feng (MBS ’12)
- Brian Feth (MBS ’05)
- Janelle and John Fluharty (MBS ’06)
- Yvonne Frame
- Susan Friedman
- Weaver Gaines
- Jessica Garcia
- Robert Garrahy
- Omar Goya (MBS ’04)
- Maria George (MBS ’09)
- Pratyusha Ghoshal (MBS ’12)
- Harold and Sandy Goldberg (Parent ’10)
- Jeffrey Grabley (MBS ’02)
- Larry Grill
- Mary Jo Gracia
- Matt Grzesik (MBS ’05)
- Alice Han (Parent ’10)
- Angella Cassey
- Sara and Wade Crow (MBS ’03)
- Jessica and Michael Cummings (MBS ’12)
- Milan Dalal (MBS ’12)
- Polina Datsyna (MBS ’06)
- Andrew Daugherty (MBS ’09)
- Brad Davis (MBS ’11)
- Ryan Davis
- Michael DeGiorgio (Parent ’12)
- Judy Marie DeGiorgio (Parent ’12)
- Marcus and Kristina DeMaster (MBS ’12)
- Fran Dang (MBS ’06)
- Richard Der Jr (MBS ’12)
- Eureka Dias (MBS ’08)
- Thomas DiRocco (MBS ’09)
- Vincent Eng (MBS ’07)
- Tim and Barbara Erwin
- Citian Feng (MBS ’12)
- Brian Feth (MBS ’05)
- Janelle and John Fluharty (MBS ’06)
- Yvonne Frame
- Susan Friedman
- Weaver Gaines
- Jessica Garcia
- Robert Garrahy
- Omar Goya (MBS ’04)
- Maria George (MBS ’09)
- Pratyusha Ghoshal (MBS ’12)
- Harold and Sandy Goldberg (Parent ’10)
- Jeffrey Grabley (MBS ’02)
- Larry Grill
- Mary Jo Gracia
- Matt Grzesik (MBS ’05)
- Alice Han (Parent ’10)
- Angella Cassey
- Sara and Wade Crow (MBS ’03)
- Hsiao-Wei and Boashi (Nguyen) Lu
- Juan Pablo Macdonald (MBS ’11)
- John and Lillian Maguire
- Kyle Malik (MBS ’12)
- Swaroop Mallela
- Line Martinez (MBS ’02)
- Siddhartha Mathur (MBS ’05)
- Ryan McComb (MBS ’12)
- John McNamara (MBS ’07)
- Kathryn McKeown
- Silvia Meletath (MBS ’11)
- Isaac Meldenfandt (MBS ’08) and
  Naomi Arana (MBS ’08)
- Arin Miller
- Joshua Miller (MBS ’12)
- Frank and Irma Milling (Parent ’12)
- Wendy Milling (MBS ’12)
- Bandish Momin (MBS ’11)
- Deborah Monroe
- Shefali Nagrani (MBS ’11)
- Chitr Narayan (MBS ’12)
- Minhads Nathan
- Andy Nguyen (MBS ’12)
- Mimi Nguyen (MBS ’12)
- Thi Nguyen (MBS ’08)
- Angelika Niemiec
- Rigzin Norbu
- Tiffany (McEnich) O’Brien (MBS ’02)
- Anthony and Linda O’Keefe
- Candace Olliff (MBS ’09)
- Abimbola Onikoro (MBS ’12)
- Fernando Ortiz
- Amy Orwen
- Corey Ozar (MBS ’11)
- Harish Padmanabhan (MBS ’04)
- Kaufal Parikh (MBS ’09)
- Biranchi and Smita Patna (PPM ’11)
- Adam Ray
- Benjamin Pavlik (MBS ’09)
- Ryan Peeler (MBS ’07)
- Rohit Peremattam (MBS ’06)
- Nithya Periasamy (MBS ’10)
- Michelle Peace (MBS ’11)
- Andrew Peters (MBS ’06)
- Steve Pettit
- Pioneer Hi-Bred International, Inc
- Deborah and Ronald Pollock
  (Parent ’11)
- Durgaasam Ramachandhravarnami
  (MBS ’12)
- James Rankin, Jr. (MBS ’09)
- Manukiran Ravi (MBS ’12)
- Arinath and Sumita Ray
- Lauren Rivera (MBS ’12)
- Anil Rivero-Villegas
- William and Mary Roberts
- Kristina Roskos (MBS ’09)
- Russo Partners LLC
- Asavani Sathish-Charlu
  and Ramesh SadeVar (MBS ’06)
- David Sadava
- Ronald and Pauline
  Sakamoto (Parent ’13)
- Marc Salata
- Jose Salazar
- Christopher and
  Cheryl Salmen (MBS ’04)
- Kristina and Antonio Sanchez
  (PPM ’12)
- Sergio and Sarah Sanchez
  (PPM ’11)
- Amit Sarasua (MBS ’12)
- Karen Schneider
- Garry Seid (MBS ’03)
- Trevor Sell (’11)
- Joshua Sem (MBS ’02) and
  Terri Peon (MBS ’02)
- Ashish Shah and Payal Kamdar
  (MBS ’04)
- Louis Shamal (MBS ’09)
- Arusha Shankar (MBS ’11)
- Jenny Shang (MBS ’09)
- Jung-so Shin (MBS ’11)
- Damir Shokatko (MBS ’12)
- Dipika Shringapura (PPM ’11)
- Monica Sierra
- Ranjith and Neela Silva
- Nicole Sindy (MBS ’09)
- Hans Smith (MBS ’09)
- Reid Snowden (MBS ’09)
- Dessy and Bill Spuyten (Parent ’08)
- Brano (Schuetz) Spuzzillo (MBS ’08)
- Nathan Stazewski
- Paige Skinn
- Janat Stenpa
- Thomas Storey (MBS ’03)
- Brian Sullivan
- Gemma Sunwoo (Parent ’04)
- Hun Sunwoo (Parent ’04)
- Kirsten Suurkask (MBS ’04)
- Kirilynn Svay
- Sameen Syed (MBS ’14)
- Annie Tam (Parent ’07)
- Robert Tapella (MBS ’07)
- Hirshikesh Thakur (MBS ’12)
- Chandana Thorat (MBS ’11)
- Jane and David Tillrell
- Ilya Tolstoyev and Diana
  Kozlovska
- Jimmy and Sofia Toro
- Rudy Toy (MBS ’12)
- Andrew Urszynski (MBS ’12)
- Satish Varmi (MBS ’08)
- Phyllis Vanderwier (Parent ’08)
- Raghavan Vasudevan (MBS ’09)
- Augustine Velasco
- Cyrus Virdieh (MBS ’09)
- Duane and Puannam Wakuta
  (Parent ’10)
- Tiffany Wan (MBS ’10)
- Michael Wang (MBS ’10)
- Wenli Wang (MBS ’02)
- Brian Watkins (MBS ’08)
- John Weaver (MBS ’12)
- Breanne Weismann-Dufresne
  (MBS ’03)
- Malin Wang
  (Parent ’12)
- Joel West
- Joseph and Mary Will
  (Parent ’02)
- Dennis Wilson
- Gary and Margaret Wilson
  (Parent ’02)
- James and Patricia Wilson
  (Parent ’09)
- Laura Wilson (MBS ’12)
- Amanda Wirtz
- Christine Wolf (MBS ’03)
- Jennifer Wang (MBS ’08)
- Joy Wang (MBS ’12)
- Stephanie Wang (MBS ’12)
- Jennifer Woll (PPM ’10)
- Alexander and Meredith Wu
  (MBS ’22)
- Xin Claire Xu (MBS ’12)
- Jarred Yacob (MBS ’12)
- Ranga Yorgiogudda (MBS ’10)
- Jean Yoo (PPC ’11)
- Jeff Young (MBS ’12)
- Rina Zakharov
- Mathew Zamei (MBS ’04) and
  Navene Wuana
- Kari and Kevin Zitar
  (Parent ’02)
- Daniel and Mahvili Zuvolta

- Jane and David Tillrell
- Ilya Tolstoyev and Diana
  Kozlovska
- Jimmy and Sofia Toro
- Rudy Toy (MBS ’12)
- Andrew Urszynski (MBS ’12)
- Satish Varmi (MBS ’08)
- Phyllis Vanderwier (Parent ’08)
- Raghavan Vasudevan (MBS ’09)
- Augustine Velasco
- Cyrus Virdieh (MBS ’09)
- Duane and Puannam Wakuta
  (Parent ’10)
- Tiffany Wan (MBS ’10)
- Michael Wang (MBS ’10)
- Wenli Wang (MBS ’02)
- Brian Watkins (MBS ’08)
- John Weaver (MBS ’12)
- Breanne Weismann-Dufresne
  (MBS ’03)
- Malin Wang
  (Parent ’12)
- Joel West
- Joseph and Mary Will
  (Parent ’02)
- Dennis Wilson
- Gary and Margaret Wilson
  (Parent ’02)
- James and Patricia Wilson
  (Parent ’09)
- Laura Wilson (MBS ’12)
- Amanda Wirtz
- Christine Wolf (MBS ’03)
- Jennifer Wang (MBS ’08)
- Joy Wang (MBS ’12)
- Stephanie Wang (MBS ’12)
- Jennifer Woll (PPM ’10)
- Alexander and Meredith Wu
  (MBS ’22)
- Xin Claire Xu (MBS ’12)
- Jarred Yacob (MBS ’12)
- Ranga Yorgiogudda (MBS ’10)
- Jean Yoo (PPC ’11)
- Jeff Young (MBS ’12)
- Rina Zakharov
- Mathew Zamei (MBS ’04) and
  Navene Wuana
- Kari and Kevin Zitar
  (Parent ’02)
- Daniel and Mahvili Zuvolta
LEADERSHIP

SENior ADMINISTRATION

SHeldon M. Schuster, PhD
President and Professor

JAMES D. STERLING, PhD
President for Academic Affairs and Dean of Faculty; Sidney J. Weinberg Jr.
Professor of Applied Life Sciences

ROBERT W. CARAGHER
Vice President for Finance and Operations

KAREN SCHNEIDER
Vice President for Advancement

ELIZABETH WRIGHT
Assistant Vice President/Secretary to the Board of Trustees

E. SOFIA TORO
Associate Dean of Admissions and Financial Aid

BOARD OF TRUSTEES AND EMERITI

JOANNE P. DIGENHARO
President, Center for Excellence in Education

DENNIS M. FENTON
Former Executive Vice President, Amgen

JUDITH A. HEYBOER
Human Resources Consultant; Former Senior Vice President of Human Resources, Genentech Inc.

PETER BARTON HUTT
Senior Counsel, Covington & Burling LLP

ALICE T. KANE
Partners, Duane & Morris, LLP

BERNARD E. KURY
Former Vice President and General Counsel, Guidant Corporation

GREGG LAPOINTE
Former CEO, Sigma-Tau Pharmaceuticals

RODNEY S. MARKIN
Associate Vice Chancellor for Business Development and Chief Technology Officer, University of Nebraska Medical Center

ARTHUR D. RIGGS
Director Emeritus, Beckman Research Institute, City of Hope

MAXINE SAVITZ
Vice-President, National Academy of Engineering, Former General Manager for Technology Partnerships - Honeywell

SHELDON M. SCHUSTER
President, Keck Graduate Institute of Applied Life Sciences

MARK STEVENSON
President and Chief Operating Officer, Life Technologies

MURLI TOLANEY
Chairman Emeritus, MWH Global, Inc.

MARISA E. VINCENT
Vice President, Clinical Research and Development, Agensys

JAMES F. WIDEROEN
Senior Vice President of Global Customer Operations, Beckman Coulter, Inc. (retired)

RICHARD M. McCONNELL
Former President, Pioneer Hi-Bred International

CLIFFORD A. MILLER
Strategic Counsel, Shamrock Holdings

HARLYNE J. NORRIS
Trustee, The Kenneth T. and Eileen L. Norris Foundation

STANFORD N. PHILPS
Chairman, S.N. Phelps & Co. and Clear Springs Land Co.

RICHMOND WOLF
Vice President and Investment Analyst, Capital World Investors

LUAN WU
Program Executive, Global University Programs, IBM Technology Strategy and Innovation

HENRY E. RIGGS
President Emeritus, Keck Graduate Institute of Applied Life Sciences

TRUSTEES EMERITI

ALICE S. HUANG
Senior Faculty Associate in Biology, California Institute of Technology

HOWARD B. KECK, JR.
President, Brighton Distributing Company

JOHN D. LELAND, JR.
Consultant and Former Managing Director, Dreiser RCM Global Investors

RICHARD L. MCCONNELL
Former President, Pioneer Hi-Bred International

LOUIS T. ROSSO
Chairman Emeritus, Beckman Coulter, Inc.

STEPHEN J. RYAN
President, Dohrney Eye Institute

JACK L. STARK
President Emeritus, Claremont McKenna College

ROBERT E. TRANQUADA
Emeritus Professor of Medicine & Public Policy, University of Southern California

SIDNEY J. WEINBERG, JR.**
Chair Emeritus Former Senior Director, The Goldman Sachs Group

FOUNDING TRUSTEES

JOHN D. MAGUIRE
Clifford A. Miller
HENRY E. RIGGS
JACK L. STARK
ROBERT E. TRANQUADA
SIDNEY J. WEINBERG, JR.**

*Chair, Board of Trustees
**Deceased

FELLOWSHIPS FUNDED FOR ACADEMIC YEAR 2011-2012

ALLERGAN FOUNDATION

ANNENBERG FOUNDATION

ASTELLAS USA FOUNDATION

ANNETTE AND DANIEL BRADBURY

BRISTOL-MYERS SQUIBB FOUNDATION

CATHERINE AND FRANCIS BURKZ FOUNDATION

BONNIE BUSKENBERG

ROBERT AND WINIFRED CURRY

ROBERT A. DAY

DENNIS AND LINDA FENTON

GILEAD

GENENTECH

HEART FOUNDATIONS

H. VICTOR HANSEN

FLETCHER JONES FOUNDATION

JOHN AND SANDRA LELAND

GEORGE H. MAYR

ANN PEPPERS FOUNDATION

PIONEER HI-BRED

ARTHUR AND JANE RIGGS

HANK AND GAYLE RIGGS

SIDNEY J. WEINBERG JR. FOUNDATION
Faculty members come to KGI from well-established academic positions and successful biotechnology companies. They combine impressive university credentials with a keen awareness of the industry’s latest developments to bring new ideas and innovations into their classrooms and labs.
The KGI Advisory Council provides industry insight, marketplace feedback, and support for KGI’s corporate outreach. The council includes leaders from biotech, pharmaceutical, medical device, service, and bio companies.

ADVOCATE COUNCIL

- Todd G. Abraham, Vice President, Operations, EndoLogics
- David Aedwan, Vice President, Corporate Strategy, Edwards Lifesciences
- Robert Balter, Biotechnology Executive
- Randy Berholtz, Executive Vice President, General Counsel and Secretary, Apricus Biosciences, Inc.
- Sean Caffey, Co-Founder, Chairman & CEO, MinaPumps, LLC and RepliPharm, Inc.
- Linda Castle, Research director for Pioneer Hi-Bred, a DuPont company
- Raymond W. Cohen, CEO, Veissi Vaccins, Inc.
- Stephen G. Daggett, Director, Product Support R & D, Ortho-Clinical Diagnostics
- Jamie Danienberg, Vice President, Translational Medicine and Tailored Therapeutics, Eli Lilly & Co.
- Catherine Farrell, US Business Development Executive, Epistem
- David Flores, President and CEO, BioCentury
- Weaver R. Gaines, Director, Florida Research Consortium
- Sean R. Gallagher, Vice President, Chief Technology Officer, UVP LLC
- Chris Garabedian, President and CEO, Sarepta Therapeutics
- John D. Gerace, Vice President & General Manager, PCR Systems Business Unit, Life Technologies
- Paul Grint, President, Genexa, Inc.
- Ross A. Grossman, Vice President, Human Resources, Regeneron Pharmaceuticals
- Kenneth Griggs, Science Fellow, Monsanto Co.
- Lawrence P. Guindon, Principal, Cadieux and Associates LLC
- Richard Hamilton, President and CEO, Corex
- Kevin Harley, Vice President Human Resources, Illumina
- Allan Harris, Vice President, Corporate Strategic Planning, Beckman Coulter
- Dennis Huang, Vice President, Biologics Manufacturing and Development, Allergan
- Mark Jasek, Director, Global Medical Affairs - Glaucoma, Allergy, and Glaucoma Surgery
- Matthew Jenessatis, President & CEO of OCTane
- Vanessa King, Vice President, Business Development, deCODE
- Thomas G. Klopak, Executive Consultant in Medical Devices
- Kenneth James Livak, Senior Scientific Fellow, Fluidigm Corp.
- Brenda Mann, Co-Founder & Chief Operating Officer, Research and Development, ScintiX Animal Care
- Roger Marchetti, Executive Vice President, Human Resources, CareFusion Corporation
- Alan M. Mendelson, Founder and General Partner, Axinn Venture Partners
- Tony Page, Managing Director, siQ
- Ulise Peschke, National Biotech Sales Manager, NorsBioMedical
- MK Raheja, Global Head of Cataract & Cornel R&D, Abbott Medical Optics
- Bill Rich, Vice President, International Supply Chain, Angen
- J. David Rozzell, President & CEO, Carylyx, Inc.
- George M. Savage, MD, Co-Founder, Chief Medical Officer, Proteus Digital Health
- James Schaeffer, Executive Director of Licensing & External Research-West Coast, Merck
- Randy Schatzman, Co-Founder, President and CEO, Alder Pharmaceuticals Inc.
- Steve Shire, Staff Scientist and Group Leader in the Late Stage Pharmaceutical and Device Development Department, Genentech
- Harmeet Sidhu, Chief Scientific Officer, OnXtra
- Alex Suh, Managing Director, California Technology Ventures, LLC
- James D. Talton, Co-founder, President and CEO, Nanotera Pharmaceuticals
- J. Russell Teagarden, Former Vice President, Scientific Affairs, Advanced Clinical Science & Research, Medco Health Solutions, Inc.
- Robert Tenerowicz, Vice President, Supply Chain, BioMarin Pharmaceutical, Inc.
- Gino van Herke, Executive Director, Nourarta Institutes for BioMedical Research
- Joseph J. Villafranca, Biotechnology Executive
- Srijan Viswanathan, Biotechnology Executive
- James A. Wilkins, President, Sensorn
- Stephen Zweig, President & CEO, Cliomere

ADVISORS EMERITI

- Bruce Alberts, Professor, University of California, San Francisco
- Gary Augusta, Consultant
- Luis J. Berga, CEO, Luis Berga & Associates
- Rolando Braver, Director, Business Development & Licensing, Life Technologies
- Alexander M. Caron, University Professor of Law and Medicine, Pacific Center for Health Policy and Ethics
- Shu Chen, Professor and Director, Whittaker Institute of Biomedical Engineering, University of California at San Diego
- T. (Terry) Forcht Dagle, MD, Partner, HLM Venture Partners
- Larry Gold, Founder, CEO and Chairman of the Board, SomaLogic
- BJ Hull, Site Director (retired), Gilead Sciences, Inc.
- Robert L. Jones, Vice President, Human Resources, CancerVax
- Vaughan M. Kallian, Vice Chairperson, Head of Commercial Operations and Therapeutic Franchise (retired), Millennium Pharmaceuticals
- Gail Maders, President, BayBio
- Alfred E. Mann, Chairman and CEO, Advanced Bioscience
- Stephen J. McCorman, CEO, Exela
- Michael A. Musaalem, Chairman and CEO, Edwards Lifesciences
- Stephen D. O’Connor, CEO, Nanostream
- Joseph D. Panetta, President and CEO, Biocom
- Kal Ramnarayan, Founder, President and Chief Scientific Officer, Sapient Discovery
- John B. Rogers, President and CEO, EcoArray
- Tony Russo, Co-founder and CEO, Russo Partners
- David Sadava, Prichard Family Foundation Professor of Biology, Joint Science Department, The Claremont Colleges
- Thomas P. Sgambato, President and CEO, Americas Biotech Distributor
- Brian Sullivan, Product Development Team Leader, ICx Agentase
- Daniel Vapnek, Founding Senior Vice President of Research (Retired), Angen
- J. Craig Venter, President, The Center for the Advancement of Genomics
- Bradley Wigglesworth, Site Manager (retired), Gilead
- Rick Winningham, CEO, Theravance
CORKS AND FOUNDATIONS

Corporations and foundations annually support KGI with gifts for special programs or investment, employee matching funds, or fellowships and endowments. The following supporters contributed to KGI during 2011-2012.

AETNA FOUNDATION, INC.
ALLERGAN FOUNDATION
AMGEN FOUNDATION
THE STEVE AND BONNIE ANDERSON GIFT FOUNDATION
ASTELLAS USA FOUNDATION
AT&T FOUNDATION
JOHN D. BALDERSCHWEILER AND MARLENE R. KONNAR FOUNDATION
BECKMAN COULTER, INC
BECKMAN COULTER FOUNDATION
BRISTOL-MYERS SQUIBB COMPANY
T. M. PARSONS FOUNDATION
THE ANN PEPPERS FOUNDATION
PIERCE FOUNDATION
THE ANN PEPPERS FOUNDATION
PIONEER H-BRED INTERNATIONAL, INC
PRUDENTIAL FOUNDATION
RUSSELL FOUNDATION
THE H. RUSSELL SMITH FOUNDATION
THE SYDNEY J. WEINBERG, JR. FOUNDATION

FELLOWSHIPS AND PROFESSORSHIPS

The following contributors made gifts to establish endowments, fellowships or special programs that benefited KGI in 2011-2012.

ALLERGAN, INC.
ASTELLAS USA FOUNDATION
BECKMAN COULTER FOUNDATION
DANIEL BRADBURY
BRISTOL-MYERS SQUIBB FOUNDATION
CATHERINE AND FRANCIS BURZI FOUNDATION
T. M. PARSONS FOUNDATION
ROBERT E. AND WINIFRED B. CURRY FOUNDATION
Dennis and Linda Fenton
Gentech, Inc.
Gilead
H. Victor Hansen
Fletcher Jones Foundation
THOMAS LEE
ANN PEPPERS FOUNDATION
ARTHUR D. RIGGS
HANK AND GAYLE RIGGS
ROSE HILLS FOUNDATION
SIDNEY J. WEINBERG, JR. FOUNDATION

ALUMNI BOARD

NICOLE SINDY, MBS '09
Current president
Veracyte, Inc., Clinical Research Associate II
AANCHAL KAMRA, MBS '09
University Health Network Research, Business Operations Analyst
ADITYA KELAR, MBS '10
Amgen, Competitive Intelligence Analyst
ANDREW PETERS, MBS '06
UBS, Associate Analyst
BILL CASEY, MBS '06
Hastings College of Law, student
JENNIFER BOYD, MBS '08
UCSD, Clinical Operations Manager
LOUIS SHAMEL, MBS '09
Life Technologies, M&A Associate
RANEE SHACKEL, MBS '06
Onyx Pharmaceuticals, Senior Manager Corporate Development
### Financial Statements

#### Statements of Revenues

**June 30, 2012**

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuition and fees (net of tuition discount)</td>
<td>$3,002,591</td>
</tr>
<tr>
<td>Private gifts and grants</td>
<td>$1,988,506</td>
</tr>
<tr>
<td>Private contracts</td>
<td>$158,951</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$1,687,267</td>
</tr>
<tr>
<td>Investment income</td>
<td>$3,072,816</td>
</tr>
<tr>
<td>Other revenues</td>
<td>$1,066,215</td>
</tr>
</tbody>
</table>

**Total Revenues**

$12,186,346

**June 30, 2011**

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuition and fees (net of tuition discount)</td>
<td>$2,481,295</td>
</tr>
<tr>
<td>Private gifts and grants</td>
<td>$1,483,083</td>
</tr>
<tr>
<td>Private contracts</td>
<td>$185,547</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$1,743,677</td>
</tr>
<tr>
<td>Investment income</td>
<td>$2,225,945</td>
</tr>
<tr>
<td>Other revenues</td>
<td>$853,059</td>
</tr>
</tbody>
</table>

**Total Revenues**

$8,972,606

#### Statements of Expenses

**June 30, 2012**

<table>
<thead>
<tr>
<th>Expense</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Instruction</td>
<td>$3,804,435</td>
</tr>
<tr>
<td>Research</td>
<td>$2,496,598</td>
</tr>
<tr>
<td>Academic support</td>
<td>$2,129,851</td>
</tr>
<tr>
<td>Student services</td>
<td>$1,463,779</td>
</tr>
<tr>
<td>Institutional support</td>
<td>$4,817,038</td>
</tr>
</tbody>
</table>

**Total Expenses**

$14,711,701

**June 30, 2011**

<table>
<thead>
<tr>
<th>Expense</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Instruction</td>
<td>$3,480,362</td>
</tr>
<tr>
<td>Research</td>
<td>$2,604,096</td>
</tr>
<tr>
<td>Academic support</td>
<td>$1,883,743</td>
</tr>
<tr>
<td>Student services</td>
<td>$1,506,736</td>
</tr>
<tr>
<td>Institutional support</td>
<td>$4,410,886</td>
</tr>
</tbody>
</table>

**Total Expenses**

$13,885,823

#### Statements of Deficiencies of Revenues over Expenses

**June 30, 2012**

$(2,525,355)

**June 30, 2011**

$(4,913,217)

#### Statements of Other Changes in Net Assets

**June 30, 2012**

<table>
<thead>
<tr>
<th>Other Change</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial adjustment</td>
<td>$(3,819)</td>
</tr>
<tr>
<td>Realized and unrealized investment</td>
<td>$(2,726,308)</td>
</tr>
<tr>
<td>Gain (loss) on disposal of buildings and equipment</td>
<td>$(408,234)</td>
</tr>
</tbody>
</table>

**Total Other Changes in Net Assets**

$(2,321,893)

**June 30, 2011**

<table>
<thead>
<tr>
<th>Other Change</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial adjustment</td>
<td>$(1,139)</td>
</tr>
<tr>
<td>Realized and unrealized investment</td>
<td>$(7,678,932)</td>
</tr>
<tr>
<td>Gain (loss) on disposal of buildings and equipment</td>
<td>$(17,914)</td>
</tr>
</tbody>
</table>

**Total Other Changes in Net Assets**

$(7,659,880)

#### Net Assets - Beginning of Year

**June 30, 2012**

$56,959,644

**June 30, 2011**

$52,112,396

#### Net Assets - End of Year

**June 30, 2012**

$52,112,396

**June 30, 2011**

$56,959,644

#### Financial Statements

For the Year Ended JUNE 30, 2012

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuition and fees (net of tuition discount)</td>
<td>$3,002,591</td>
</tr>
<tr>
<td>Private gifts and grants</td>
<td>$1,988,506</td>
</tr>
<tr>
<td>Private contracts</td>
<td>$158,951</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$1,687,267</td>
</tr>
<tr>
<td>Investment income</td>
<td>$3,072,816</td>
</tr>
<tr>
<td>Other revenues</td>
<td>$1,066,215</td>
</tr>
</tbody>
</table>

**Total Revenues**

$12,186,346

**June 30, 2011**

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuition and fees (net of tuition discount)</td>
<td>$2,481,295</td>
</tr>
<tr>
<td>Private gifts and grants</td>
<td>$1,483,083</td>
</tr>
<tr>
<td>Private contracts</td>
<td>$185,547</td>
</tr>
<tr>
<td>Federal grants and contracts</td>
<td>$1,743,677</td>
</tr>
<tr>
<td>Investment income</td>
<td>$2,225,945</td>
</tr>
<tr>
<td>Other revenues</td>
<td>$853,059</td>
</tr>
</tbody>
</table>

**Total Revenues**

$8,972,606

#### Financial Statements

For the Year Ended JUNE 30, 2012

<table>
<thead>
<tr>
<th>Expense</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Instruction</td>
<td>$3,804,435</td>
</tr>
<tr>
<td>Research</td>
<td>$2,496,598</td>
</tr>
<tr>
<td>Academic support</td>
<td>$2,129,851</td>
</tr>
<tr>
<td>Student services</td>
<td>$1,463,779</td>
</tr>
<tr>
<td>Institutional support</td>
<td>$4,817,038</td>
</tr>
</tbody>
</table>

**Total Expenses**

$14,711,701

**June 30, 2011**

<table>
<thead>
<tr>
<th>Expense</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Instruction</td>
<td>$3,480,362</td>
</tr>
<tr>
<td>Research</td>
<td>$2,604,096</td>
</tr>
<tr>
<td>Academic support</td>
<td>$1,883,743</td>
</tr>
<tr>
<td>Student services</td>
<td>$1,506,736</td>
</tr>
<tr>
<td>Institutional support</td>
<td>$4,410,886</td>
</tr>
</tbody>
</table>

**Total Expenses**

$13,885,823

#### Financial Statements

For the Year Ended JUNE 30, 2012

<table>
<thead>
<tr>
<th>Deficiencies of revenues over expenses</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Tuition and fees)</td>
<td>$(3,819)</td>
</tr>
<tr>
<td>(Private gifts and grants)</td>
<td>$(2,726,308)</td>
</tr>
<tr>
<td>(Federal grants and contracts)</td>
<td>$(408,234)</td>
</tr>
</tbody>
</table>

**Total Deficiencies of Revenues over Expenses**

$(2,525,355)

**June 30, 2011**

<table>
<thead>
<tr>
<th>Deficiencies of revenues over expenses</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Tuition and fees)</td>
<td>$(1,139)</td>
</tr>
<tr>
<td>(Private gifts and grants)</td>
<td>$(7,678,932)</td>
</tr>
<tr>
<td>(Federal grants and contracts)</td>
<td>$(17,914)</td>
</tr>
</tbody>
</table>

**Total Deficiencies of Revenues over Expenses**

$(4,913,217)

#### Financial Statements

For the Year Ended JUNE 30, 2012

<table>
<thead>
<tr>
<th>Other Changes in Net Assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial adjustment</td>
<td>$(3,819)</td>
</tr>
<tr>
<td>Realized and unrealized investment</td>
<td>$(2,726,308)</td>
</tr>
<tr>
<td>Gain (loss) on disposal of buildings and equipment</td>
<td>$(408,234)</td>
</tr>
</tbody>
</table>

**Total Other Changes in Net Assets**

$(2,321,893)

**June 30, 2011**

<table>
<thead>
<tr>
<th>Other Changes in Net Assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actuarial adjustment</td>
<td>$(1,139)</td>
</tr>
<tr>
<td>Realized and unrealized investment</td>
<td>$(7,678,932)</td>
</tr>
<tr>
<td>Gain (loss) on disposal of buildings and equipment</td>
<td>$(17,914)</td>
</tr>
</tbody>
</table>

**Total Other Changes in Net Assets**

$(7,659,880)

#### Financial Statements

For the Year Ended JUNE 30, 2012

<table>
<thead>
<tr>
<th>Net Assets - Beginning of Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$14,035,794</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$8,742,972</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>$29,333,630</td>
</tr>
</tbody>
</table>

**Total Net Assets**

$52,112,396

**June 30, 2011**

<table>
<thead>
<tr>
<th>Net Assets - Beginning of Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$19,728,027</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>$7,918,826</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>$29,312,791</td>
</tr>
</tbody>
</table>

**Total Net Assets**

$56,959,644
"I've gotten great experience at KGI and at my Amgen internship. If I stay along this path, I feel that I could go off to any setting anywhere in the world and be able to make a significant contribution." – Andrew Vo, MBS '13

"There's a large amount of teamwork at KGI, which as a PhD really helps you to break the habit of thinking only for yourself. There's a certain level of frustration involved but it's getting harder and harder to function in the business world if you don't have an eye for that." – Ramya Kartikeyan, PPM '12